Company profile: Biodesix
1.1 - Company Overview
Company description
- Provider of data-driven lung cancer diagnostic testing and biopharma services, offering the IQLung Treatment Guidance strategy—GeneStrat targeted, GeneStrat NGS genomic, and VeriStrat proteomic tests—to inform NSCLC treatment decisions, plus Nodify Lung testing (Nodify CDT and Nodify XL2) to assess malignancy risk in lung nodules and support early detection.
Products and services
- IQLung™ Treatment Guidance: An integrated NSCLC testing strategy combining GeneStrat® targeted (cfDNA/cRNA detecting fusions, indels, point mutations), GeneStrat NGS® (52-gene panel), and VeriStrat® (blood-based immune classifier) to guide treatment
- GeneStrat NGS® Genomic Test: An NGS-based 52-gene panel that detects diverse variants to identify advanced-stage NSCLC patients eligible for targeted therapies or clinical trial enrollment
- VeriStrat® Proteomic Test: A blood-based host immune classifier delivering predictive and prognostic insights for NSCLC, independent of ECOG performance status, mutation status, PD-L1 expression, treatment choice, and therapy line
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Biodesix
BioMark Diagnostics
HQ: Canada
Website
- Description: Provider of oncology-focused metabolomics-based cancer detection solutions, including a liquid biopsy metabolic panel for early lung cancer diagnosis using urine and plasma, a non-invasive SSAT1 assay leveraging an FDA-approved drug to detect elevated enzyme levels in cancers, a metabolomics-driven detection platform, lung cancer early detection studies, and cancer education videos.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioMark Diagnostics company profile →
Artbio
HQ: United States
Website
- Description: Provider of clinical-stage alpha radioligand medicines and enabling technologies, including AB001, a 212Pb-based radiopharmaceutical candidate for prostate cancer in Phase I/II trials; AlphaDirect technology for isolating Pb-212 to enable distributed manufacturing; and a distributed end-to-end manufacturing network to deliver therapeutic candidates rapidly and flexibly.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Artbio company profile →
Attovia Therapeutics
HQ: United States
Website
- Description: Provider of a biologics platform and pipeline of biotherapeutics for immune-mediated diseases, featuring ATTOBODY to generate binders and biparatopic biologics as alternatives to IgG-based medicines; programs include ATTO-1310 (IL31), ATTO-002 (IL31 x IL13), ATTO-004 (novel GPCR), and ATTO-005 (IBD).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Attovia Therapeutics company profile →
Asuragen
HQ: United States
Website
- Description: Provider of mRNA- and microRNA-based diagnostics for molecular oncology and early cancer detection, offering Signature Genetic and Oncology Testing products and industry-leading controls and standards engineered with its patented Armored technology. Portfolio includes qPCR BCR-ABL1 monitoring for CML, HTT CAG repeat testing, TRIO workflow for FMR1/SMN1/2/CFTR, SARS-CoV-2 controls, and carrier screening solutions under development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Asuragen company profile →
Aletheia Therapeutics
HQ: United States
Website
- Description: Provider of precision oncology therapeutics based in Fort Collins, Colorado, developing and commercializing clinical-stage cancer therapies that simultaneously target two or more of DNA repair, T-cell activation, and metabolic dysfunction, tailored to the make-up of a patient's cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aletheia Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Biodesix
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Biodesix
2.2 - Growth funds investing in similar companies to Biodesix
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Biodesix
4.2 - Public trading comparable groups for Biodesix
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →